Bulgarian Randomized, Double-Blind, Placebo-Controlled Ivermectin Study Shows Positive Results Against COVID-19
According to reports from Bulgarian media outlet Economic.BG,
the study (EUDRACT2020-002091-12)
involved recruiting and enrolling individuals with positive PCR tests and onset of symptoms no greater than 7 days prior to the commencement of the treatment.
The patients
were administered the drug at a dose of 400 μg/kg ivermectin as well as those receiving placebo per day for a three consecutive day period.100 patients
were included in this randomized study with both the Huvemex and the placebo arms.Results
As reported in Economic.BG, the results reveal that
the study drug accelerated the clearance of the virus (as evidenced by reading of RT-PCR tests) by day 3 and 4 post treatment start date.
The investigators also
observed marked improvement in patient clinical condition for those in the study drug arm based on the WHO 9- category ordinal scale).As compared to placebo,
the participants receiving the ivermectin based drug fared better, statistically than those in the placebo group.Interestingly,
the study sponsors
observed that the ivermectin-based drug appeared associated with the suppression and normalization of important inflammation biomarkers, considered by many scientists as an important indicator of pathological processes associated with COVID-19 disease progression—including D-Dimer and C-Reactive Protein (CRP).The sponsors
shared with Bulgarian press that the study drug on average started to make its positive impact felt.